[go: up one dir, main page]

CO5570660A2 - Indazolilpirrolotriazinas c-6 modificadas - Google Patents

Indazolilpirrolotriazinas c-6 modificadas

Info

Publication number
CO5570660A2
CO5570660A2 CO05057043A CO05057043A CO5570660A2 CO 5570660 A2 CO5570660 A2 CO 5570660A2 CO 05057043 A CO05057043 A CO 05057043A CO 05057043 A CO05057043 A CO 05057043A CO 5570660 A2 CO5570660 A2 CO 5570660A2
Authority
CO
Colombia
Prior art keywords
substituted
heterocycle
aryl
alkyl
group
Prior art date
Application number
CO05057043A
Other languages
English (en)
Inventor
Gregory D Vite
Harold Mastalerz
John F Kadow
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO5570660A2 publication Critical patent/CO5570660A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

1.- Un compuesto de la fórmula I caracterizado porque:R se selecciona del grupo que consiste de arilo, arilo sustituido, heterociclo, y heterociclo sustituido;R1 se selecciona del grupo que consiste de alquilo y alquilo sustituido;R2 se selecciona del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido; o, R2 puede estar ausente;X se selecciona del grupo que consiste de un enlace, O, S, C(R3)2, C(R3)3, NR3; y N(R3)2;R3 se selecciona independientemente del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido.9.- Una composición farmacéutica, caracterizada porque comprende el compuesto de conformidad con la reivindicación 1 y un portador farmacéuticamente aceptable.
CO05057043A 2002-12-13 2005-06-13 Indazolilpirrolotriazinas c-6 modificadas CO5570660A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43319002P 2002-12-13 2002-12-13

Publications (1)

Publication Number Publication Date
CO5570660A2 true CO5570660A2 (es) 2005-10-31

Family

ID=32595133

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05057043A CO5570660A2 (es) 2002-12-13 2005-06-13 Indazolilpirrolotriazinas c-6 modificadas

Country Status (27)

Country Link
US (2) US6916815B2 (es)
EP (1) EP1569937B1 (es)
JP (1) JP4511367B2 (es)
KR (1) KR101073801B1 (es)
CN (2) CN1726216A (es)
AR (1) AR042450A1 (es)
AT (1) ATE534648T1 (es)
AU (1) AU2003300877B2 (es)
BR (1) BR0316755A (es)
CA (1) CA2509650C (es)
CO (1) CO5570660A2 (es)
DK (1) DK1569937T3 (es)
ES (1) ES2374393T3 (es)
HR (1) HRP20050535A2 (es)
IS (1) IS7890A (es)
MX (1) MXPA05006164A (es)
NO (1) NO20052733L (es)
NZ (1) NZ540338A (es)
PE (1) PE20040805A1 (es)
PL (1) PL377517A1 (es)
PT (1) PT1569937E (es)
RS (1) RS20050441A (es)
RU (1) RU2356903C2 (es)
TW (1) TW200420565A (es)
UA (1) UA80591C2 (es)
WO (1) WO2004054514A2 (es)
ZA (1) ZA200504507B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
ATE418546T1 (de) 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
HRP20040988A2 (en) * 2002-04-23 2005-06-30 Bristol-Myers Squibb Company A Delaware (Usa) Corp Pyrrolo-triazine aniline compounds useful as kinas
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP2186811A1 (en) 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
MXPA05008183A (es) 2003-02-05 2005-10-05 Bristol Myers Squibb Co Proceso para preparar pirrolotriazina como inhibidores de cinasa.
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine
US20060014741A1 (en) * 2003-12-12 2006-01-19 Dimarco John D Synthetic process, and crystalline forms of a pyrrolotriazine compound
US7064203B2 (en) * 2003-12-29 2006-06-20 Bristol Myers Squibb Company Di-substituted pyrrolotriazine compounds
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7102002B2 (en) * 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7102003B2 (en) * 2004-07-01 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
ATE497975T1 (de) * 2005-04-18 2011-02-15 Novo Nordisk As Il-21-varianten
US7402582B2 (en) * 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
EA200801945A1 (ru) 2006-03-07 2009-02-27 Бристол-Маерс Сквибб Компани Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
AU2007336184A1 (en) * 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
US20090083483A1 (en) * 2007-09-24 2009-03-26 International Business Machines Corporation Power Conservation In A RAID Array
US8166326B2 (en) * 2007-11-08 2012-04-24 International Business Machines Corporation Managing power consumption in a computer
US20090132842A1 (en) * 2007-11-15 2009-05-21 International Business Machines Corporation Managing Computer Power Consumption In A Computer Equipment Rack
US8041521B2 (en) * 2007-11-28 2011-10-18 International Business Machines Corporation Estimating power consumption of computing components configured in a computing system
WO2009137201A1 (en) 2008-04-04 2009-11-12 Cv Therapeutics, Inc. Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
JP2011516496A (ja) * 2008-04-04 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するためのピロロトリアジノン誘導体
WO2009126311A1 (en) * 2008-04-11 2009-10-15 The University Of Texas, M.D. Anderson Cancer Center Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
US8103884B2 (en) 2008-06-25 2012-01-24 International Business Machines Corporation Managing power consumption of a computer
US8041976B2 (en) * 2008-10-01 2011-10-18 International Business Machines Corporation Power management for clusters of computers
US8514215B2 (en) * 2008-11-12 2013-08-20 International Business Machines Corporation Dynamically managing power consumption of a computer with graphics adapter configurations
TW201035100A (en) 2008-12-19 2010-10-01 Cephalon Inc Pyrrolotriazines as ALK and JAK2 inhibitors
MX2011009413A (es) * 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
WO2011112689A2 (en) * 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
CN103450204B (zh) 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
US9724352B2 (en) 2012-05-31 2017-08-08 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof
ES2616026T3 (es) * 2013-03-11 2017-06-09 Bristol-Myers Squibb Company Pirrolopiridazinas como inhibidores de canales de iones potasio
JP6395798B2 (ja) * 2013-03-11 2018-09-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのピロロトリアジン
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015081783A1 (zh) * 2013-12-06 2015-06-11 江苏奥赛康药业股份有限公司 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
CN111533708B (zh) * 2020-06-12 2021-03-16 上海馨远医药科技有限公司 一种手性n-叔丁氧羰基吗啉-3-羧酸的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908056A (en) * 1986-04-25 1990-03-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
ATE243697T1 (de) 1995-12-08 2003-07-15 Pfizer Substitutierte heterozyclische derivate als crf antagonisten
CA2263566C (en) 1996-08-28 2003-09-09 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
WO2000071129A1 (en) * 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
GEP20063915B (en) * 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
ATE418546T1 (de) * 2002-04-23 2009-01-15 Bristol Myers Squibb Co Als kinase inhibitoren geeignete arylketonpyrrolotriazin-verbindungen
HRP20040988A2 (en) * 2002-04-23 2005-06-30 Bristol-Myers Squibb Company A Delaware (Usa) Corp Pyrrolo-triazine aniline compounds useful as kinas
TW200400034A (en) * 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
US7102001B2 (en) * 2003-12-12 2006-09-05 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine

Also Published As

Publication number Publication date
US20050222153A1 (en) 2005-10-06
BR0316755A (pt) 2005-10-25
EP1569937A4 (en) 2007-08-08
JP4511367B2 (ja) 2010-07-28
CN101723948A (zh) 2010-06-09
PT1569937E (pt) 2012-01-04
PE20040805A1 (es) 2004-11-20
PL377517A1 (pl) 2006-02-06
NO20052733L (no) 2005-07-07
ZA200504507B (en) 2006-08-30
NZ540338A (en) 2008-05-30
KR101073801B1 (ko) 2011-10-13
EP1569937A2 (en) 2005-09-07
NO20052733D0 (no) 2005-06-07
CA2509650C (en) 2007-10-30
UA80591C2 (en) 2007-10-10
US7148220B2 (en) 2006-12-12
TW200420565A (en) 2004-10-16
US6916815B2 (en) 2005-07-12
AR042450A1 (es) 2005-06-22
MXPA05006164A (es) 2005-08-26
JP2006509826A (ja) 2006-03-23
AU2003300877A1 (en) 2004-07-09
RU2005120650A (ru) 2006-01-20
CN1726216A (zh) 2006-01-25
WO2004054514A3 (en) 2004-10-07
DK1569937T3 (da) 2012-01-02
IS7890A (is) 2005-06-10
WO2004054514A2 (en) 2004-07-01
ATE534648T1 (de) 2011-12-15
AU2003300877B2 (en) 2010-02-18
HRP20050535A2 (en) 2005-12-31
CA2509650A1 (en) 2004-07-01
ES2374393T3 (es) 2012-02-16
RS20050441A (sr) 2007-04-10
US20040142931A1 (en) 2004-07-22
RU2356903C2 (ru) 2009-05-27
EP1569937B1 (en) 2011-11-23
KR20050084242A (ko) 2005-08-26

Similar Documents

Publication Publication Date Title
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
DK1265606T3 (da) Celleadhæsionsinhibitorer
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
SE9904652D0 (sv) Novel Compounds
IS6309A (is) Kínasólínafleiður
FI972326A0 (fi) Uusi amidinonaftyylijohdannainen tai sen suola
BR0013041A (pt) Composto heterociclico e composição farmacêutica para tratar e prevenir doenças mediadas por cgmp-pde, seu uso e método
ATE260275T1 (de) Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one
DE69127690D1 (de) Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
UY25986A1 (es) Complejo del inhibidor de ras-farnesiltransferasa y sulfobutiléter-7-beta-ciclodextrina o 2-hidroxipropil-beta-ciclodextrina y método.
KR960700045A (ko) 혈관신생 저해제 및 신규 화합물
TR200202806T2 (tr) 4-Triflorometilsulfinilpirazol türevi hazırlama süreci
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
CO5640109A2 (es) Compuestos triciclicos inhibidores de la farnesisl proteino transferasa y composiciones farmaceuticas que los contienen
PT1157998E (pt) Compostos heterociclicos seus intermediarios e inibidores da elastase
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
AR044175A1 (es) Compuestos de cefemo
CO5140099A1 (es) Ciertas caprolactamas sustituidas, composiciones farmaceuticas que las contienen, y su uso en el tratamiento de tumores
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
PT1140942E (pt) Inibidores da prenil-transferase
AR023528A1 (es) Derivados de ciclobuten-3,4-diona, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FC Application refused